Clinical Trial

The Prevalence, Risk Factors and Optimal Biopsy Protocol of BE

Recruiting
View on ClinicalTrials.gov →
Record status
This record was last updated May 11, 2023 (before its estimated December 31, 2025 completion). Its status may not reflect the trial's current state.
Summary
Detections of goblet cells and dysplasia are crucial for diagnosis and determining the surveillance program of Barrett's esophagus (BE). However, the optimal biopsy numbers and their yield rates of intestinal metaplasia (IM) and dysplasia are still uncertain, especially in Asia. The aim of this study was to determine the optimal biopsy protocol of BE.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2023-04-14.
Status change: Not Yet Recruiting → Recruiting 2023-05-09
Trial Details
NCT Number NCT05818072
Lead Sponsor E-DA Hospital
Conditions Barrett's Esophagus, Intestinal Metaplasia
Enrollment 165 participants
Start Date 2023-03-13
Primary Completion 2025-12-31 (estimated)
Study Completion 2026-12-31 (estimated)
Updated on ClinicalTrials.gov 2023-05-11